PharmaShots | Incisive News in 3 Shots

Subscribe Now

Fasenra

AstraZeneca Reports Results of Fasenra (benralizumab) in P-III OSTRO Study for Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca Reports Results of Fasenra (benralizumab) in P-III OSTRO Study for Chronic Rhinosinusitis with Nasal Polyps

September 10, 2020

AstraZeneca Receives the US FDA's Orphan Drug Designation for its First Respiratory Biologic Fasenra (benralizumab) to Treat Eosinophilic Esophagitis

AstraZeneca Receives the US FDA's Orphan Drug Designation for its First Respiratory Biologic Fasenra (benralizumab) to Treat Eosin...

August 28, 2019

AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

April 4, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us